Can CV Monitoring Warnings Or REMS Restrictions Save Abbott's Meridia?
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency presents four regulatory options for the Endocrinologic and Metabolic Drugs Advisory Committee's Sept. 15 review of sibutramine's cardiovascular safety, ranging from continued marketing with no labeling changes to withdrawal.